MYCO and MYCOF Related Headlines
Go Back- Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
- Mydecine Innovations Group Announces Director Resignation
- Mydecine Announces Update Regarding the Special Access Program
- Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
- Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
- Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
- Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
- Mydecine Innovations Announces Closing of Prospectus Supplement Financing
- Mydecine Innovations Group Files Prospectus Supplement
- Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023
- Mydecine Innovations Group Provides Corporate Update
- Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
- Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023
- Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
- Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
MYCO and MYCOF Related Press Releases
Go Back- Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
- Mydecine Innovations Group Announces Director Resignation
- Mydecine Announces Update Regarding the Special Access Program
- Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
- Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
- Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
- Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
- Mydecine Innovations Announces Closing of Prospectus Supplement Financing
- Mydecine Innovations Group Files Prospectus Supplement
- Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023
- Mydecine Innovations Group Provides Corporate Update
- Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
- Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023
- Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
- Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues